Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity

  • Song, Min (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Do, HyunHee (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Kwon, Oh Kwang (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Yang, Eun-Ju (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Bae, Jong-Sup (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Jeong, Tae Cheon (College of Pharmacy, Yeungnam University) ;
  • Song, Kyung-Sik (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Lee, Sangkyu (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
  • Received : 2013.12.20
  • Accepted : 2014.03.12
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Thelephoric acid is an antioxidant produced by the hydrolysis of polyozellin, which is isolated from Polyozellus multiplex. In the present study, the inhibitory effects of polyozellin and thelephoric acid on 9 cytochrome P450 (CYP) family members (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were examined in pooled human liver microsomes (HLMs) using a cocktail probe assay. Polyozellin exhibited weak inhibitory effects on the activities of all 9 CYPs examined, whereas thelephoric acid exhibited dose- and time-dependent inhibition of all 9 CYP isoforms ($IC_{50}$ values, $3.2-33.7{\mu}M$). Dixon plots of CYP inhibition indicated that thelephoric acid was a competitive inhibitor of CYP1A2 and CYP3A4. In contrast, thelephoric acid was a noncompetitive inhibitor of CYP2D6. Our findings indicate that thelephoric acid may be a novel, non-specific CYP inhibitor, suggesting that it could replace SKF-525A in inhibitory studies designed to investigate the effects of CYP enzymes on the metabolism of given compounds.

Keywords

References

  1. Chang, T. K., Chen, G. and Waxman, D. J. (1995) Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J. Pharmacol. Exp. Ther. 274, 270-275.
  2. Chung, W. G., Park, C. S., Roh, H. K., Lee, W. K. and Cha, Y. N. (2000) Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn. J. Pharmacol. 84, 213-220. https://doi.org/10.1254/jjp.84.213
  3. Di, Y. M., Chow, V. D., Yang, L. P. and Zhou, S. F. (2009) Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr.Drug Metab. 10, 754-780. https://doi.org/10.2174/138920009789895507
  4. Emoto, C., Murase, S., Sawada, Y., Jones, B. C. and Iwasaki, K. (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab. Pharmacokinet. 18, 287-295. https://doi.org/10.2133/dmpk.18.287
  5. Franklin, M. R. and Hathaway, L. B. (2008) 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab.Dispos. 36, 2539-2546. https://doi.org/10.1124/dmd.108.023549
  6. Guengerich, F. P. (1997) Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43, 7-35. https://doi.org/10.1016/S1054-3589(08)60200-8
  7. Guidance for Industry Drug interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling (2006). Available at: .
  8. Huang, Z. and Waxman, D. J. (2001) Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. 8, 450-458. https://doi.org/10.1038/sj.cgt.7700325
  9. Hwang, J. S., Song, K. S., Kim, W. G., Lee, T. H., Koshino, H. and Yoo, I. D. (1997) Polyozellin, a new inhibitor of prolyl endopeptidase from Polyozellus multiplex. J. Antibiot. (Tokyo) 50, 773-777. https://doi.org/10.7164/antibiotics.50.773
  10. Jahng, Y., Kwon, O. K. and Lee, S. (2012) In vitro inhibitory effect of luotonin A on human CYP1A. Arch. Pharm. Res. 35, 2199-2203. https://doi.org/10.1007/s12272-012-1218-0
  11. Kim, H., Choi, H. K., Jeong, T. C., Jahng, Y., Kim, D. H., Lee, S. H. and Lee, S. (2013) Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. Food Chem. Toxicol. 51, 33-37. https://doi.org/10.1016/j.fct.2012.09.013
  12. Kwak, J. Y., RHee, I. K., Lee, K. B., Hwang, J. S., Yoo, I. D. and Song, K. S. (1999) Thelephoric acid and kynapcin-9 in mushroom polyozellus multiflex inhibit prolyl endopeptidase in vitro. J. Microbiol. Biotechn. 9, 798-803.
  13. Lee, S. K., Kim, G. H., Kim, D. H., Jahng, Y. and Jeong, T. C. (2007) Identification of a tryptanthrin metabolite in rat liver microsomes by liquid chromatography/electrospray ionization-tandem mass spectrometry. Biol. Pharm. Bull. 30, 1991-1995. https://doi.org/10.1248/bpb.30.1991
  14. Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J. and Tsutsui, M. (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26, 681-693. https://doi.org/10.3109/00498259609046742
  15. Porubsky, P. R., Meneely, K. M. and Scott, E. E. (2008) Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem. 283, 33698-33707. https://doi.org/10.1074/jbc.M805999200
  16. Schenkman, J. B., Wilson, B. J. and Cinti, D. L. (1972) Dimethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)--in vivo and in vitro effects of metabolism by rat liver microsomes--formation of an oxygenated complex. Biochem. Pharmacol. 21, 2373-2383. https://doi.org/10.1016/0006-2952(72)90389-9
  17. Song, M., Hong, M., Lee, M. Y., Jee, J. G., Lee, Y. M., Bae, J. S., Jeong, T. C. and Lee, S. (2013) Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6. Food Chem. Toxicol. 59, 549-553. https://doi.org/10.1016/j.fct.2013.06.055
  18. Spatzenegger, M. and Jaeger, W. (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev. 27, 397-417. https://doi.org/10.3109/03602539508998329
  19. Sridhar, J., Liu, J., Foroozesh, M. and Stevens, C. L. (2012) Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies. Molecules 17, 9283-9305. https://doi.org/10.3390/molecules17089283
  20. Yano, J. K., Hsu, M. H., Griffin, K. J., Stout, C. D. and Johnson, E. F. (2005) Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol. 12, 822-823. https://doi.org/10.1038/nsmb971
  21. Zhou, S. F., Yang, L. P., Zhou, Z. W., Liu, Y. H. and Chan, E. (2009) Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 11, 481-494. https://doi.org/10.1208/s12248-009-9127-y

Cited by

  1. Investigation of selective inhibitory effects of glycyrol on human CYP 1A1 and 2C9 vol.46, pp.10, 2016, https://doi.org/10.3109/00498254.2015.1131345
  2. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions vol.68, pp.1, 2015, https://doi.org/10.1124/pr.115.011411
  3. Acetylshikonin is a novel non-selective cytochrome P450 inhibitor vol.38, pp.9, 2017, https://doi.org/10.1002/bdd.2101